$KYTX News

Last published 4h ago

4h agoKYTXKyverna Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
4h agoKYTXKyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial ResultsGlobeNewswireBLA submission for miv-cel in SPS completed with request for priority review
3d agoKYTXKyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA NeurologyGlobeNewswirePublication reinforces miv-cel's potential to deliver durable clinical benefit with a single dose, enabled by miv-cel's unique construct, and become the first approved therapy in SPS and first approved CAR
3d agoKYTXKyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA NeurologyGlobeNewswirePublication reinforces miv-cel's potential to deliver durable clinical benefit with a single dose, enabled by miv-cel's unique construct, and become the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease
6d agoKYTXKyverna Therapeutics to Present at the Jefferies London Healthcare ConferenceGlobeNewswireEMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune
2w agoKYTXKyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026GlobeNewswireSingle-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores
2w agoKYTXDid Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireShareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket
3w agoKYTXKyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS TorontoGlobeNewswireMiv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies Deep B-cell depletion demonstrated
1mo agoKYTXKyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026GlobeNewswireFull one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no
1mo agoKYTXKyverna SPS and MG Longer-term Follow-up Data Conference Call - KYVERNA THERAPEUTICS INCEarnings Call TranscriptsGood morning and welcome to the Caverna Therapeutics Conference Call. At this time, all participants are in a listen-only mode. A Q&A session will follow the prepared remarks. Please note this call is being recorded. I w
1mo agoKYTXMorgan Stanley 24th Annual Global Healthcare Conference - KYVERNA THERAPEUTICS INCEarnings Call TranscriptsAll right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Oltz, one of the biotech analysts, and it's my pleasure to introduce Werner Beadle, CEO of Kyver
2mo agoKYTXWells Fargo 21st Annual Healthcare Conference - KYVERNA THERAPEUTICS INCEarnings Call TranscriptsAll right, everyone, I think we'll get started here with our next fireside. So good afternoon. My name is Derek Archilla. I'm one of the Wells Fargo biotech analysts. With us next for our fireside is Kyverna Therapeutics
2mo agoKYTXKyverna Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireEMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune
3mo agoKYTXKyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial ResultsGlobeNewswireFDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology On track to
3mo agoKYTXKyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-celGlobeNewswireEMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with
4mo agoKYTXKyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage TransitionGlobeNewswireEMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today
5mo agoKYTXJeffries Global Healthcare Conference in New York - KYVERNA THERAPEUTICS INCEarnings Call TranscriptsThanks, Natasha, and to the Jefferies team for hosting this great event. Really excited to share with you the progress we're making here at Kyverna as we continue to pioneer our way forward, bringing autologous therapies
5mo agoKYTXKyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid ArthritisGlobeNewswireMajority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36 Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset Miv-cel continues
5mo agoKYTXKyverna Therapeutics Names Greg Martini as Chief Financial OfficerGlobeNewswireEMERYVILLE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today
6mo agoKYTXKyverna Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireEMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases,
6mo agoKYTXKyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial ResultsGlobeNewswirePositive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated Miv-cel pivotal trial primary analysis results in SPS demonstrated robust,
6mo agoKYTXKyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial OfficerGlobeNewswireEMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases,
6mo agoKYTXKyverna AAN Conference Call - KYVERNA THERAPEUTICS INCEarnings Call TranscriptsGood morning and thank you for joining us today. We will be discussing the primary analysis from our KAISA-8 Registrational Trial of Mevocaptogen Avalucel or MEVCEL, formerly referred to as KYV-101 and Stiff Person Syndr
6mo agoKYTXKyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual MeetingGlobeNewswireSingle-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS Data underscore
6mo agoKYTXKyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 WeeksGlobeNewswire100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial Totality of efficacy and safety data reinforces miv-cel's differentiated and
7mo agoKYTXKyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026GlobeNewswireEMERYVILLE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with
7mo agoKYTXKyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireAdvancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment for FDA-aligned Phase
8mo agoKYTXKyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026GlobeNewswireLate-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated KYSA-6 Phase 2 data in generalized myasthenia gravis (gMG)
8mo agoKYTXKyverna Therapeutics to Participate in Upcoming March Investor ConferencesGlobeNewswireEMERYVILLE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today
8mo agoKYTXKyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of DirectorsGlobeNewswireSravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval experience to support
9mo agoKYTXKyverna Therapeutics Appoints Mayo Pujols as Chief Technology OfficerGlobeNewswireEMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today
10mo agoKYTXKyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare ConferenceGlobeNewswireAdvancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026 First patient enrolled in
10mo agoKYTXKyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare ConferenceGlobeNewswireEMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune
11mo agoKYTXKyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common StockGlobeNewswireEMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX) ("Kyverna"), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune
11mo agoKYTXKyverna Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswireEMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX) ("Kyverna"), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune
11mo agoKYTXKYSA-8 Topline Results for Stiff Person Syndrome - KYVERNA THERAPEUTICS INCEarnings Call TranscriptsGood morning, and welcome to the Caverna Therapeutics Investor Conference Call. At this time, all participants are in listen-only mode. A Q&A session will follow the prepared remarks. Please note that this call is being
11mo agoKYTXKyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person SyndromeGlobeNewswireLandmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel achieved
11mo agoKYTXKyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person SyndromeGlobeNewswireEMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases,
12mo agoKYTXKyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswireTopline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive interim Phase 2 data
1y agoKYTXKyverna Therapeutics to Present at the Jefferies London Healthcare ConferenceGlobeNewswireEMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune
1y agoKYTXKyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford FinanceGlobeNewswireInitial funding of $25 million from the first of four tranches Facility strengthens Kyverna's financial flexibility, further supporting advancement of its late-stage indications in generalized myasthenia gravis (gMG)
1y agoKYTXKyverna Therapeutics Interim Phase 2 Results for MG Conference Call - KYVERNA THERAPEUTICS INCEarnings Call TranscriptsGood morning, and welcome to the Caverna Therapeutics Investor Conference Call. At this time, all participants are on a listen-only mode. A Q&A session will follow the prepared remarks. Please note that this call is bein
1y agoKYTXKyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025GlobeNewswireCompelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically meaningful
1y agoKYTXKyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025GlobeNewswireKYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a
1y agoKYTXKyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia GravisGlobeNewswireEMERYVILLE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases,
1y agoKYTXKyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMSGlobeNewswireKYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101 continues to
1y agoKYTXKyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025GlobeNewswireOral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate by year-end 2025
1y agoKYTXKyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL EventGlobeNewswireKYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase 3 trial design for
1y agoKYTXKyverna Therapeutics to Present at Upcoming Investor Conferences in SeptemberGlobeNewswireEMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases,
1y agoKYTXKyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsGlobeNewswireTopline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) andBLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients